Bayesian dose-finding phase I trial design incorporating pharmacokinetic assessment in the field of oncology
Author:
Affiliation:
1. Data Science, Astellas Pharma Global Development, Inc.; IL USA
2. Clinical Pharmacology, Astellas Pharma Inc.; Tokyo Japan
3. Department of Biomedical Statistics and Bioinformatics; Kyoto University Graduate School of Medicine; Kyoto Japan
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology,Statistics and Probability
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/pst.1890/fullpdf
Reference20 articles.
1. Integration of physiologically-based pharmacokinetic modeling into early clinical development: an investigation of the pharmacokinetic nonlinearity;Zhou;CPT Pharmacometrics Syst Pharmacol,2015
2. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans;Gianni;J Clin Oncol,1995
3. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma;Ajani;J Clin Oncol,2005
4. Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity;Broker;Clin Cancer Res,2006
5. Pharmacologically guided phase I clinical trials based upon preclinical drug development;Collins;J Natl Cancer Inst,1990
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Adaptive phase I–II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies;Clinical Trials;2024-01-11
2. An extended Bayesian semi‐mechanistic dose‐finding design for phase I oncology trials using pharmacokinetic and pharmacodynamic information;Statistics in Medicine;2023-12-18
3. A Bayesian optimal interval design for dose optimization with a randomization scheme based on pharmacokinetics outcomes in oncology;Pharmaceutical Statistics;2023-08-06
4. Comparison of design methods for a safety run-in phase of a phase II clinical trial;Clinical Trials;2023-01-11
5. Exposure driven dose escalation design with overdose control: Concept and first real life experience in an oncology phase I trial;Contemporary Clinical Trials Communications;2022-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3